Daiichi Sankyo submits application for oncolytic virus teserpaturev (G47∆) for treatment of patients with malignant glioma in Japan

Daiichi Sankyo

5 January 2020 - Daiichi Sankyo and the University of Tokyo are collaboratively developing teserpaturev, which has received SAKIGAKE designation and orphan drug designation in Japan.

Daiichi Sankyo today announced it has submitted a new drug application to Japan’s Ministry of Health, Labour and Welfare for teserpaturev (G47∆), an oncolytic virus, for the treatment of patients with malignant glioma.

The Japan new drug application submission, which took place on 28 December 2020, is based on results of a single-arm phase 2 clinical trial conducted by Dr. Todo at the University of Tokyo in patients with residual or recurrent glioblastoma tumours, which met its primary outcome for one year survival rate.

Read Daiichi Sankyo press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Dossier , Japan